The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
about
Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statementCellular and molecular mechanisms of metformin: an overviewComparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.Development and validation of an electronic health record-based chronic kidney disease registry.Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort studyCardiovascular safety profile of currently available diabetic drugs.Sulfonylurea receptor as a target for molecular imaging of pancreas beta cells with (99m)Tc-DTPA-glipizide.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Chronic total artery occlusions in noninfarct-related coronary arteries.Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetesCardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus.Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Is gliclazide a sulfonylurea with difference? A review in 2016.Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk.Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.Comment on: Pantalone et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33:1224-1229.Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.Response to Comment on: Pantalone et al. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A Retrospective Analysis. Diabetes Care 2010;33:1224–1229.Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study.The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review.Diabetes and the direct secondary use of electronic health records: Using routinely collected and stored data to drive research and understanding
P2860
Q26783199-024A2B80-DF2E-46DA-A00D-2EBE9AE31BC3Q27013561-CD021988-BC7E-4D4C-8094-2310130B2E6AQ31095975-26B9D329-BFAF-4BE9-B8B2-12AB4A12988AQ34497258-4EC44781-A1F0-467B-8D9D-6E406697035CQ34644993-6C15FF84-A16A-464C-9309-A21E4746FF01Q34971736-CF58BEA4-3425-4BF5-AE6E-9B9845D3E2E4Q37398362-564C6CE6-2C49-46EB-A176-C4F51EC2B234Q37577162-2FBD9C94-E201-44D5-B708-D96955714C4EQ37600928-3E224235-90BA-4534-AEC2-EECB03E8F89EQ37714791-5D3B5822-D8C9-42FD-B163-D2B6D5D7DB51Q38068353-22823E27-4CE1-4151-BBCC-5EC6D0E8F2BAQ38258938-AD74C34E-3092-4F92-8D5C-AA0CEDB91DDBQ38364806-21AF0C11-B5A4-4043-8D00-234EB5EC75D2Q38374279-74DFC8B2-8ED5-4370-B096-42B19261A73FQ38524435-C7276034-D90F-4AC5-B246-D1753931FBB6Q38754132-A0405EBE-6FA4-4527-9436-F4EAE1BCB3ACQ38765310-C17B5F04-6263-4D56-A463-4C293D579AC3Q40992057-9A5F9DD5-7317-4229-AF32-7B03A701F29BQ42738237-CF566815-8106-4DB6-944F-335E5583B194Q43901204-476D6139-EF57-4E2B-82FE-FEAB3D0B0C81Q44802551-BB8CF5D3-8097-4293-B4F9-BEF0875FC48FQ45036323-D22282B4-B58A-44C5-87EB-5FE2D7031A7AQ46887711-D6A9E1CA-2EA4-49AD-91ED-BE3434CA28F9Q47305063-F52F0C34-3A33-49A9-AD9E-6B065BFA4335Q47419443-51A6C769-899D-4700-A4A9-E6FB614FCD19Q47733021-56CCE6BF-9C59-4412-815D-F3DB6D315E66Q52603541-AB124E60-3440-40E7-BEC2-7CA739101068Q57294147-BBC83FA3-64E4-4A65-B662-BE9B0A3ADAC0
P2860
The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The risk of overall mortality ...... apy: a retrospective analysis.
@ast
The risk of overall mortality ...... apy: a retrospective analysis.
@en
type
label
The risk of overall mortality ...... apy: a retrospective analysis.
@ast
The risk of overall mortality ...... apy: a retrospective analysis.
@en
prefLabel
The risk of overall mortality ...... apy: a retrospective analysis.
@ast
The risk of overall mortality ...... apy: a retrospective analysis.
@en
P2093
P2860
P356
P1433
P1476
The risk of overall mortality ...... apy: a retrospective analysis.
@en
P2093
Ashish Atreja
Changhong Yu
Kevin M Pantalone
Michael W Kattan
Robert S Zimmerman
Susana Arrigain
P2860
P304
P356
10.2337/DC10-0017
P407
P50
P577
2010-03-09T00:00:00Z